Evolus, Inc. (EOLS)

Evolus, Inc. stock experienced a significant decline of 60.64% over the past six months, with a 52-week range between $3.86 and $12.28. The Q4 and full-year 2025 earnings report on March 3, 2026, showed profitability, leading to a stock price increase of over 35% on March 4, 2026. The company projects total net revenues between $327 million and $337 million for 2026 and anticipates full-year profitability. Insider selling activity has been observed in the past three months, with insiders selling $797,184.00 in company stock.

The demand for injectables in the aesthetic market exhibits some seasonality, with the third quarter typically being a seasonally lower period and the fourth quarter generally expected to be the strongest. The toxin market is showing solid demand, and the company has observed that the economic environment in Europe has been stronger relative to the U.S. Evolus has also noted rising demand for beauty products, particularly those targeting wrinkles and frown lines, with high customer satisfaction reflected in approximately 71% reorder rates.

Evolus, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry, focusing on medical products for aesthetic indications. Its major products include Jeuveau, a botulinum toxin type A formulation for frown lines, and Evolysse, a line of injectable hyaluronic acid dermal fillers. Evolus anticipates FDA approval for Evolysse Sculpt in Q4 2026.

Evolus, Inc. has operations in the United States, Canada, Europe (including Great Britain, Germany, Austria, and Italy), and Australia. The company is headquartered in Newport Beach, California, USA, and has an operational presence in Dublin, Ireland.

Evolus has cultivated a strong brand reputation, driven by product performance and strategic initiatives. Jeuveau has been recognized as the fastest-growing neurotoxin in the U.S. for four consecutive years, with its U.S. market share surpassing 14%. The company successfully introduced Evolysse to over 3,000 customers. The Evolus Rewards loyalty program has grown to over 1.4 million enrolled consumers, with high customer satisfaction reflected in approximately 71% reorder rates. The company's achievement of profitability in Q4 2025 further bolstered its reputation.

Approximately 90.69% of Evolus, Inc.'s stock is held by institutions, including Nantahala Capital Management, LLC, BlackRock, Inc., and Vanguard Group Inc. The largest individual shareholder is Medytox Inc., owning 16.36% of the company. Insider ownership is relatively low, between 3.46% and 5.90%.